ArticleOncotarget2016

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.

Sandrine Tury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.